Risk of ophthalmic adverse drug reactions in patients prescribed glucagon-like peptide 1 receptor agonists: a pharmacovigilance study based on the FDA adverse event reporting system database

FAERS reported 5003 ophthalmic adverse drug reactions associated with glucagon-like peptide 1 receptor agonists (GLP-1 RAs).

• Significant signals for ophthalmic adverse drug reactions were identified for semaglutide, liraglutide, and exenatide.
• Most of the reported ophthalmic adverse drug reactions were categorized as early failures, indicating a need for early monitoring.
• Co-medication analysis suggested that the majority of ophthalmic adverse drug reactions were primarily linked to the use of GLP-1 RAs.
• The findings highlight the need for enhanced ophthalmic surveillance in patients using GLP-1 RAs, particularly with semaglutide, dulaglutide, and exenatide.
• Recommendations include updating drug labels to provide comprehensive warnings regarding the potential ophthalmic adverse drug reactions associated with GLP-1 RA therapies.

AI simplified